HYBRID EVENT: You can participate in person at Boston, Massachusetts, USA or Virtually from your home or work.
Mayra Ramos Suzarte, Speaker at Vaccines Conferences
Keynote Presentation (In-person)
Mayra Ramos Suzarte, Center of Molecular Immunology, Cuba

Lung cancer is the first cause of death from cancer in the world and in some countries as the first cause of death for both sexes. Early diagnosis and timely therapy is successful for increasing the survival of these patients, however, the masking with frequent symptoms of other [....] » Read More

Mayra Ramos Suzarte, Speaker at Vaccines Conferences
Keynote Presentation (In-person)
Mayra Ramos Suzarte, Center of Molecular Immunology, Cuba

COVID-19 continues to be a global health problem, it is a multifactorial disease characterized by a process of hyperinflammation. Itolizumab, a humanized anti-CD6 mAb, has the Emergency Use Authorization (UEA) for patients with this disease with signs of hyperinflammation. Method [....] » Read More

Stefan Gluck, Speaker at Vaccine Research Events
Keynote Presentation (In-person)
Stefan Gluck, Jessica McDonough PhD Co-Founder Attivare, United States

The idea of using the immune system to fight cancer is over 100 years old. (Paul Ehrlich’s “Magic Bullet”). New cellular and molecular approaches over the last 2 decades or so, led to a better understanding of the immune system. Our focus became the T cell, its [....] » Read More

Sushmita Koley, Speaker at Vaccines Conferences
Oral Presentation (In-person)
Sushmita Koley, Senior Scientist Bio-Rad Laboratories, United States

One of the crucial steps in deploying plasma therapy for COVID-19 has been the development of critical assays to detect SARS-CoV-2 antibodies and evaluate their potential suitability. Unfortunately, assays that assess neutralizing antibodies involve use of live SARS-CoV-2 virus i [....] » Read More

Regina Au, Speaker at Vaccines Conferences
Oral Presentation (In-person)
Regina Au, BioMarketing insight, United States

When the COVID-19 Vaccine was developed, time was crucial and the pharmaceutical and biotechnology  companies primary goal was to get a vaccine out as soon as possible so people to get vaccinated in saving lives.  What wasn't considered which most large companies co [....] » Read More

Joseph Smyser, Speaker at Vaccine Research Events
Oral Presentation (In-person)
Joseph Smyser, The Public Good Projects, United States

Introduction: As the pandemic evolves and nations refocus on routine immunizations and vaccine-preventable outbreaks, it is critical to continue increasing vaccine demand. Misinformation threatens the success of vaccination programs across the world. Since 2017, The Public Good P [....] » Read More

Daniel Becker, Speaker at Vaccines Conferences
Oral Presentation (In-person)
Daniel Becker, KyooBe Tech GmbH, Germany

In the ongoing global Covid-19 aftermath, epidemics and pandemics triggered by microbial and viral pathogens remain a significant challenge for global vaccine production and worldwide supply. The Irradiation of target pathogens with low-energy electrons (LEEI) can reliably and [....] » Read More

Kashif Zulfiqar, Speaker at Vaccine Research Events
Oral Presentation (In-person)
Kashif Zulfiqar, Project Manager - NADRA, Pakistan

National Immunization Management System (NIMS) in Pakistan envisages to consolidate all immunization activities that are being carried out in the country, on a single intelligent platform including vaccination scheduling, vaccine administration, role based reporting, complaint [....] » Read More

Maduike Chiehiura Onwubiko Ezeibe, Speaker at Vaccines Conferences
Oral Presentation (In-person)
Maduike Chiehiura Onwubiko Ezeibe, Michael Okpara University of Agriculture, Nigeria

Viral diseases, cancers (tumors) and antimicrobial resistant infections are among the world`s biggest health challenges. Literature reveals, that HIV and COVID-19 virus (RNA viruses) are positively charged while DNA viruses and abnormal (tumor/infected) cells are negatively charg [....] » Read More

Fejiro Chinye Nwoko, Speaker at Vaccines Conferences
Oral Presentation (In-person)
Fejiro Chinye Nwoko, Nigeria Solidarity Support Fund, Nigeria

Background: The first set of vaccines arrived in Nigeria in March 2021. The National Primary Health Care Development Agency (NPHCDA) set out to vaccinate at least 70% percent of Nigeria’s eligible population i.e., 111,776,503 people, by December 2022. As of June 2021, only [....] » Read More

Nebiyu Lera Alaro, Speaker at Immunology Conferences
Oral Presentation (In-person)
Nebiyu Lera Alaro, Medecins Sans Frontieres, Ethiopia

Most global estimates indicate that more than 1 million children a year die from acute measles. The actual number of deaths may, however, be considerably higher than this. In addition, the impact of delayed mortality as a result of measles infection is only now being realized. Ma [....] » Read More

Carless Gyamfuaa Ameyaw, Speaker at Vaccine Research Events
Oral Presentation (In-person)
Carless Gyamfuaa Ameyaw, Holy Family Hospital, Ghana

Background: The contribution of immunization to humanity is invaluable, especially to children. This makes assessment of the vaccine cold chain system of any immunization programme crucial to determine its strengths and weaknesses at all levels. The World Health Organization and [....] » Read More

Bethan Charlotte Hussey, Speaker at Vaccines Conferences
Oral Presentation (In-person)
Bethan Charlotte Hussey, UK Health Security Agency, United Kingdom

The UK Health Security Agency (UKHSA) has longstanding expertise in the technological support of vaccine development through a vast array of immunological assays. In early 2020, using this valuable knowledge, scientists within UKHSA were able to rapidly develop a live virus micro [....] » Read More

Indira Acharya, Speaker at Vaccine Development Congress
Oral Presentation (In-person)
Indira Acharya, Medstar, United States

however ANA, rheumatoid factor Reactive arthritis after various vaccinations has been previously described but such kind of reaction after mpox vaccination has not been previously reported. Here we present a case of recently diagnosed reactive arthritis following intradermal mpox [....] » Read More

Navneet Bichha, Speaker at Vaccine Development Congress
Oral Presentation (In-person)
Navneet Bichha, IIHMR University, India

Background: The global outbreak of COVID-19 has had a substantial effect on the conduct of scientific research worldwide with a need for fast-track evidence generation in vaccine development through newer innovations and technologies to control the spread of infection and reduce [....] » Read More

Nzolameso makaya Jennifer, Speaker at vaccine conferences
Poster Presentation (In-person)
Nzolameso makaya Jennifer, Hopital general de reference de kimbanseke pierre fokom, Congo

70% of people over 65 are hypertensive; high blood pressure increases the risk of exposure to cardiovascular disease (myocardial infarction and heart failure) and stroke. This is a public health problem, given the aging of the population. There are few studies carried out in e [....] » Read More

Vincent Omondi, Speaker at Vaccine Research Events
Poster Presentation (In-person)
Vincent Omondi, Clinton Health Access Initiative, Kenya

The COVID-19 pandemic has had a significant impact on global healthcare services, including routine immunization programs. In particular, the pandemic has disrupted human papillomavirus (HPV) vaccination efforts, which are critical in preventing HPV-related cancers. This review e [....] » Read More

Khalid Jebril Shrwani, Speaker at Vaccine Research Events
Poster Presentation (In-person)
Khalid Jebril Shrwani, Public Health Authority, Saudi Arabia

Middle East respiratory syndrome coronavirus (MERS-CoV) has emerged as a deadly pathogen with a mortality rate of up to 34.4% that can cause severe respiratory tract disease and multiorgan failure. Therefore, there is a pressing need for both successful antiviral vaccines and eff [....] » Read More

Sudhakar Bangera, Speaker at Vaccines Conferences
Keynote Presentation
Sudhakar Bangera, MBBS, MD, MMedSc, Fellow-Vaccinology Managing Partner AILEEN Clinical Research Services AILEEN, India

It’s not just the bacteria or viruses that most commonly cause life-threatening disease in human, some of them could be fungal pathogens. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infe [....] » Read More

Khursheed Anwer, Speaker at Immunology Conferences
Oral Presentation (Virtual)
Khursheed Anwer, IMUNON, Inc., United States

This presentation describes the development of PLACCINE a novel DNA vaccine platform well-suited to overcome the limitations of the current vaccines.  The PLACCINE platform leverages the inherent DNA advantages including design flexibility incorporating multi-antigen payload [....] » Read More

Jennifer Elaine Gerber, Speaker at Speaker for Vaccine Conferences- Jennifer Elaine Gerber
Oral Presentation (Virtual)
Jennifer Elaine Gerber, Johns Hopkins Bloomberg School of Public Health, United States

Background: Vaccine coverage is lower for influenza than for other vaccines, varying by age, race/ethnicity, and region. Vaccine safety concerns are common despite a lack of epidemiological evidence. We characterized vaccine hesitancy and identified associations with influenza va [....] » Read More

Paul Van Buynder, Speaker at Vaccine Research Events
Oral Presentation (Virtual)
Paul Van Buynder, Griffith University, Australia

Immune senescence and inflammaging render older persons more susceptible to severe consequences of infectious diseases and likely to exhibit poorer responses to vaccination.  Older persons need influenza, pneumococcal, herpes zoster, pertussis and SARS-CoV-2 vaccines and soo [....] » Read More

Patricia Canteri de Souza, Speaker at Vaccine Research Event
Oral Presentation (Virtual)
Patricia Canteri de Souza, State University of Londrina, Brazil

The production, extraction, and use of antibodies from birds is an innovative methodology that supports several purposes, from passive immunotherapy to prophylaxis and diagnosis of diseases. Immunoglobulins Y (IgY), produced by chickens, are functionally similar to immunoglobulin [....] » Read More

Yacob Mathai, Speaker at Vaccines Conferences
Oral Presentation (Virtual)
Yacob Mathai, Marma Health Centre, India

Medical textbooks say that modern science does not know enough about fever and there is no uniform definition. Physicians do not know the purpose of fever. Because fever is believed to be dangerous to the body, modern science has not looked at what our bodies have done wi [....] » Read More

Godwin Pancras, Speaker at Vaccines Conferences
Oral Presentation (Virtual)
Godwin Pancras, Muhimbili University of Health and Allied Sciences, Tanzania, United Republic of

Making proven intervention available to the host community is increasingly becoming a moral obligation than a researcher’s discretion. This study aimed to explore whether host communities of HIV vaccine trials ought to access the vaccines at no or subsidized princes. A case [....] » Read More

Ming Chung Kan, Speaker at Immunology Conferences
Oral Presentation (Virtual)
Ming Chung Kan, Founder of Vaxsia Biomedical Inc, Taiwan

Vaxsia has developed a self-assembled protein nanoparticle (PNP) platform, VADEX. The building block of VADEX is a fusion protein contains two functional modules: polymerization module and antigen presentation module. The polymerization module is modified from an amphipathic heli [....] » Read More

Mohammad Zorriehzahra, Speaker at Vaccines Conferences
Oral Presentation (Virtual)
Mohammad Zorriehzahra, Iranian Fisheries Science Research Institute , Iran (Islamic Republic of)

Today, with the development of technology and the expansion of genomics, the vaccine design process has been transferred from laboratory and practical research to the workroom and designs based on bioinformatics and genomic studies. This change has reduced costs and eliminated ex [....] » Read More

Ahsan Ahmed, Speaker at Vaccine Research Events
Oral Presentation (Virtual)
Ahsan Ahmed, KPC Medical College & Hospital, India

In this lecture, I want to talk about the role of vaccine in critically ill adult patients in ICU – How different vaccines are directly or indirectly help in reducing disease severity and morbidity of certain disease which are otherwise associated with high morbidity and mo [....] » Read More

Owais, Speaker at Vaccine Development Congress
Oral Presentation (Virtual)
Owais, Aligarh Muslim University, India

The scourge of tuberculosis and other intracellular infection is continuing to toll millions of human lives annually. Unfortunately, in the present scenario we are not having effective vaccines against most of the intracellular infections. For example, the only vaccine against tu [....] » Read More

Miranda Baxa, Speaker at Immunology Conferences
Oral Presentation (Virtual)
Miranda Baxa, Economist Impact, United States

In our interconnected modern world, diseases like covid-19 threaten global security and global development. More must be done to generate the political will to secure adequate, sustainable investment in vaccines and ensure equitable access around the world. The Immunisation Re [....] » Read More

Homoud Salem Aledhi Alrashidi, Speaker at Vaccines Conferences
Poster Presentation (Virtual)
Homoud Salem Aledhi Alrashidi, King Salman Hospital, Saudi Arabia

In December 2019, the coronavirus disease 2019 (COVID-19) first became identified in the market places of Wuhan, China. The first incidence of COVID-19 was identified in Saudi Arabia on March 2, 2020, and then within a month, the total number of reported instances had risen to ov [....] » Read More

Khalid Abd El Ghany, Speaker at Vaccines Conferences
Poster Presentation (Virtual)
Khalid Abd El Ghany, Post Doctor and Associate at Egyptian Drug Authority, Egypt

During the current era of the COVID-19 pandemic, the dissemination of Mucorales has been reported globally, with elevated rates of infection in India, and because of the high rate of mortality and morbidity, designing an effective vaccine against mucormycosis is a major health pr [....] » Read More

Ndjitoyap Ndam Antonin Wilson, Speaker at Vaccine Development Congress
Poster Presentation (Virtual)
Ndjitoyap Ndam Antonin Wilson, Department of Internal Medicine and Specialities, Cameroon

The hepatitis B virus infection remains a major public health problem worldwide. It can lead to a liver cirrhosis and/or hepatocellular carcinoma. The World Health Organization (WHO) has recommended the implementation of generalized vaccination programs against hepatitis B. In Ca [....] » Read More

Olivia Viscuso, Speaker at Vaccines Conferences
Poster Presentation (Virtual)
Olivia Viscuso, Mccombs school of business at the university of texas at austin, United States

Introduction In recent years, politics and business have become increasingly intertwined, with employees increasingly seeking workplaces that align with their political views (Stuckatz, 2020). The COVID-19 pandemic response introduced public health regulations that became cont [....] » Read More

Joana Kira Besecke, Speaker at Vaccines Conferences
Poster Presentation (Virtual)
Joana Kira Besecke, Fraunhofer Institute for Organic Electronics, Germany

The use of low-energy electron irradiation (LEEI) is a novel and highly efficient method for manufacturing vaccines and other pharmaceutical products. This technology provides advantages against conventional methods for virus inactivation, as the process is faster, does not requi [....] » Read More

Narjes Noori Goodarzi, Speaker at Vaccine Development Congress
Poster Presentation (Virtual)
Narjes Noori Goodarzi, Tehran University of Medical Sciences, Iran (Islamic Republic of)

Gonorrhea is an urgent antimicrobial resistance threat and its therapeutic options are continuously getting restricted. Moreover, no vaccine has been approved against it so far. Hence, the present study aimed to introduce novel immunogenic and drug targets against antibiotic-resi [....] » Read More

Scientific Programs coming soon..